![Natalie Wildenradt](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Natalie Wildenradt is currently working as an Investor Relations Contact at Ra Pharmaceuticals, Inc. She previously worked as a Senior Associate-Investor Relations at Argot Partners LLC from 2016 to 2019.
She also worked as an Investor Relations Contact at Black Diamond Therapeutics, Inc.
Anciens postes connus de Natalie Wildenradt
| Sociétés | Poste | Fin |
|---|---|---|
| BLACK DIAMOND THERAPEUTICS, INC. | Investor Relations Contact | 01/12/2021 |
Argot Partners LLC
 Argot Partners LLC Miscellaneous Commercial ServicesCommercial Services Operates as a strategic communications consultancy | Investor Relations Contact | 01/01/2019 |
| RA PHARMACEUTICALS, INC. | Investor Relations Contact | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
5
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of glomerulonephritis, kidney disease and cardiovascular disease | Health Technology |
Argot Partners LLC
Argot Partners LLC Miscellaneous Commercial ServicesCommercial Services Operates as a strategic communications consultancy | Commercial Services |
Black Diamond Therapeutics, Inc.
 Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer | Health Technology |
